Dr Agarwal's Hea
Dr Agarwal's Hea Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Future growth expectations highlighted in the transcript include: - Post-merger, AEHL shareholders will benefit from participation in AHCL's high-growth pan India story, suggesting anticipated expansion beyond current geographies. - Access to larger clinical talent pool and consolidated cash resources is expected to support expansion and efficient capital allocation. - Investment of Rs. The merger aims to create a simplified and more efficient group structure enabling faster decision-making and unified capital allocation.
From Dr Agarwal's Hea's Q1 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
2 more points from Dr Agarwal's Hea's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Dr Agarwal's Hea said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- AHCL plans a capital expenditure (CAPEX) for the construction of the flagship facility at Cathedral Road.
- A preferential allotment of approximately Rs. 70 crores from AHCL to AEHL will finance immediate fund requirements related to this CAPEX plan.
- Post allotment, AEHL's share capital will increase, with promoter holding rising slightly.
- The infusion aims to support AEHL's growth and expansion initiatives.
- The merger will enable unified capital allocation and strengthen the balance sheet, supporting future growth.
2 more points from Dr Agarwal's Hea's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Agarwal's Hea said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Dr Agarwal's Hea — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹564 Cr, net profit ₹50 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Agarwals Health Care Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality Care Ltd (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Syngene Intl. (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
- Rainbow Childrens Medicare Ltd (Q1 FY26)
Around 50% of the total planned bed additions will be on an asset-light model. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1 FY26 earnings…
Arthneeti Pro · Annual
Dr Agarwal's Hea and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Agarwal's Hea Q1 FY26 results?
Future growth expectations highlighted in the transcript include: - Post-merger, AEHL shareholders will benefit from participation in AHCL's high-growth pan India story, suggesting anticipated expansion beyond current geographies. - Access to larger clinical talent pool and consolidated cash resources is expected to support expansion and efficient capital allocation. - Investment of Rs. The merger aims to create a simplified and more efficient group structure enabling faster decision-making and unified capital allocation.
What is Dr Agarwal's Hea share price analysis?
Dr Agarwal's Hea currently shows a neutral. The stock trades at a P/E of 107.4 with a market cap of ₹15,858 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Agarwal's Hea planning capital expenditure?
AHCL plans a capital expenditure (CAPEX) for the construction of the flagship facility at Cathedral Road. - A preferential allotment of approximately Rs.
Keep Dr Agarwal's Hea on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.